Pertinently, there are active trials testing this strategy in metastatic pancreatic cancer patients using BL-8040 (motixafortide), a short synthetic peptide antagonist of CXCR4, in combination with pembrolizumab (NCT02907099) or chemotherapy (NCT02826486 and NCT03193190). This evidence concerns the gene CXCR4 and familial pancreatic carcinoma.